Back

External validation of the Systematic COronary Risk Evaluation 2 (SCORE2) model in cancer patients

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cancer and other risk factors for heart disease Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mrs Mari Nordboe Gynnild

St. Olav University Hospital, Trondheim (Norway)

7 More presentations in this session

Presentation thumbnail
ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel
Mrs J. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Ischemic and bleeding risk after ST-segment elevated myocardial infarction in patients with active cancer
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
Comparison of cardiovascular disease risk assessment tools for heart failure prediction among cancer patients
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic impact of fasting plasma glucose and myocardial flow reserve beyond other risk factors and heart disease phenotypes
Doctor D. Neglia (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cancer and other risk factors for heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Improved risk stratification with SCORE2 on top of HFA-ICOS in cancer patients without previous cardiovascular disease
thumbnail
Congress Presentation
ASCVD risk scores versus a novel cancer-specific Machine Learning-based calculator among patients with breast, colorectal, lung or prostate cancer
thumbnail
Congress Presentation
Are cancer survivors at greater risk of coronary artery disease?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources